Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Is generic prescribing acceptable in epilepsy?

F M Besag1

  • 1St Piers Lingfield, Surrey, England.

Drug Safety
|September 27, 2000
PubMed
Summary

Generic prescribing for epilepsy requires careful consideration of bioavailability and bioequivalence. Ensuring consistent anticonvulsant drug formulations and physician control is crucial for patient safety and effective seizure management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epilepsy, learning, and behavior in childhood.

Epilepsia·2012
Same author

Methsuximide reduces valproic acid serum levels.

Therapeutic drug monitoring·2002
Same author

Safety, tolerability, and pharmacokinetics of remacemide in children.

Pediatric neurology·2001
Same author

Behavioural effects of the new anticonvulsants.

Drug safety·2001
Same author

Treatment of state-dependent learning disability.

Epilepsia·2001
Same author

Epilepsy and learning disabilities:closing comments.

Epilepsia·2001

Area of Science:

  • Pharmacology
  • Clinical Pharmacy

Background:

  • Generic prescribing for epilepsy is debated, extending beyond cost to include potential toxicity and seizure control.
  • Bioavailability and bioequivalence are key considerations, with current measures potentially insufficient for all drug formulations, especially controlled-release types.

Purpose of the Study:

  • To evaluate the role and implications of generic prescribing for antiepileptic drugs.
  • To examine the bioequivalence of various anticonvulsant formulations and their impact on patient outcomes.

Main Methods:

  • Review of existing literature on phenytoin and carbamazepine bioequivalence.
  • Analysis of clinical experience and published investigations regarding anticonvulsant drug formulations.

Main Results:

  • Extensive literature on phenytoin shows likely bioequivalence issues due to its properties (poor solubility, nonlinear kinetics, narrow therapeutic range).
  • Systematic studies on carbamazepine generally indicate no major bioequivalence differences between formulations.
  • Limited information exists for other generic anticonvulsant drugs.

Conclusions:

  • Tight control over the consistency of both generic and proprietary anticonvulsant drugs is strongly recommended.
  • Physician control over prescribing decisions, based on accurate information, is essential for managing epilepsy effectively.

Related Experiment Videos